Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertension HELP
Based on 56,752 articles since 2008
|||| 21 

These are the 56752 published articles about Hypertension that originated from Worldwide during 2008-2017.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. 2016

Lynch, Bernadette M / Stern, Edward P / Ong, Voon / Harber, Mark / Burns, Aine / Denton, Christopher P. ·Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK. · Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK. · Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK. c.denton@ucl.ac.uk. ·Clin Exp Rheumatol · Pubmed #27749244.

ABSTRACT: The UK Scleroderma Study Group developed guidelines on the diagnosis and management of scleroderma renal crisis (SRC) based on best available evidence and clinical experience. SRC is characterised by the acute onset of severe hypertension and acute kidney injury. Current strategies to reduce the associated morbidity and mortality include identifying at risk patients to aid early diagnosis. ACE inhibitor therapy should be lifelong in all patients, regardless of whether they require renal replacement therapy. Patients with SRC may recover renal function up to 3 years after the crisis, most often within 12 to 18 months.

2 Guideline Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH). 2016

Moss, Jonathan G / Belli, Anna-Maria / Coca, Antonio / Lee, Michael / Mancia, Giuseppe / Peregrin, Jan H / Redon, Josep / Reekers, Jim A / Tsioufis, Costas / Vorwerk, Dierk / Schmieder, Roland E. ·Interventional Radiology Unit, North Glasgow University Hospitals, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, G12 0YN, UK. Jonathan.Moss@glasgow.ac.uk. · Department of Radiology, St George's Hospital, London, SW17 0QT, UK. · Hypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital Clínic (IDIBAPS), University of Barcelona, Barcelona, Spain. · Department of Radiology, Beaumont Hospital, Dublin 9, Ireland. · University of Milano-Bicocca, Milan, Italy. · Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic. · Research Institute INCLIVA, University of Valencia and CIBERObn, ISCIII, Madrid, Spain. · University of Amsterdam, Department of Radiology, Academic Medical Centre, Amsterdam, The Netherlands. · Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece. · Institute of Radiology, Klinikum Ingolstadt, Ingolstadt, Germany. · Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany. ·Cardiovasc Intervent Radiol · Pubmed #27658934.

ABSTRACT: -- No abstract --

3 Guideline Guideline for the diagnosis and management of hypertension in adults - 2016. 2016

Gabb, Genevieve M / Mangoni, Arduino A / Anderson, Craig S / Cowley, Diane / Dowden, John S / Golledge, Jonathan / Hankey, Graeme J / Howes, Faline S / Leckie, Les / Perkovic, Vlado / Schlaich, Markus / Zwar, Nicholas A / Medley, Tanya L / Arnolda, Leonard. ·Royal Adelaide Hospital, Adelaide, SA genevieve.gabb@sa.gov.au. · Flinders Medical Centre, Flinders University, Adelaide, SA. · The George Institute for Global Health, Sydney, NSW. · Princess Alexandra Hospital, Brisbane, QLD. · Australian Prescriber, Canberra, ACT. · Queensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD. · University of Western Australia, Perth, WA. · Royal Adelaide Hospital, Adelaide, SA. ·Med J Aust · Pubmed #27456450.

ABSTRACT: The National Heart Foundation of Australia has updated the Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults (updated December 2010). Main recommendations For patients at low absolute cardiovascular disease risk with persistent blood pressure (BP) ≥ 160/100 mmHg, start antihypertensive therapy. The decision to treat at lower BP levels should consider absolute cardiovascular disease risk and/or evidence of end-organ damage, together with accurate BP assessment. For patients at moderate absolute cardiovascular disease risk with persistent systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, start antihypertensive therapy. Treat patients with uncomplicated hypertension to a target BP of < 140/90 mmHg or lower if tolerated. Changes in management as a result of the guideline Ambulatory and/or home BP monitoring should be offered if clinic BP is ≥ 140/90 mmHg, as out-of-clinic BP is a stronger predictor of outcome. In selected high cardiovascular risk populations, aiming for a target of < 120 mmHg systolic can improve cardiovascular outcomes. If targeting < 120 mmHg, close follow-up is recommended to identify treatment-related adverse effects including hypotension, syncope, electrolyte abnormalities and acute kidney injury. Why the changes have been made A 2015 meta-analysis of patients with uncomplicated mild hypertension (systolic BP range, 140-169 mmHg) demonstrated that BP-lowering therapy is beneficial (reduced stroke, cardiovascular death and all-cause mortality). A 2015 trial comparing lower with higher blood pressure targets in selected high cardiovascular risk populations found improved cardiovascular outcomes and reduced mortality, with an increase in some treatment-related adverse events.

4 Guideline [Hypertension and pregnancy. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology]. 2016

Mounier-Vehier, Claire / Amar, Jacques / Boivin, Jean-Marc / Denolle, Thierry / Fauvel, Jean-Pierre / Plu-Bureau, Geneviève / Tsatsaris, Vassilis / Blacher, Jacques. ·Société française d'hypertension artérielle, 5, rue des Colonnes du Trône, 75012 Paris, France. Electronic address: clairemouniervehier@orange.fr. · Société française d'hypertension artérielle, 5, rue des Colonnes du Trône, 75012 Paris, France. · Collège national des gynécologues et obstétriciens français, 91, boulevard de Sébastopol, 75002 Paris, France. ·Presse Med · Pubmed #27402294.

ABSTRACT: High blood pressure in pregnancy remains, by its complications, the leading cause of morbidity and maternal and fetal mortality. The frequency (5 to 10% of pregnancies) and the potential severity of this disease, both for mother and child, encourage to standardize and to optimize our medical practices. This is the main objective of this work. If the short-term complications for the mother and child are well known, long-term ones for the mother beginning to be better identified (in particular, the risk of recurrence in a subsequent pregnancy, the risk of chronic hypertension and the increased risk of cardiovascular events). The occurrence of hypertension during pregnancy disturbs the "classic" organization of care. Several health professionals are involved, the general practitioner, obstetrician, gynecologist, midwife, cardiologist, nephrologist… There is not always a care coordinator and decisions are sometimes taken with delay. These data encouraged the French Society of Hypertension to write a consensus offering easy and efficient recommendations. Educate women and all health professionals to hypertension and its management, in line with current scientific data, is one of the major challenges of this consensus.

5 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism. 2016

Pechère-Bertschi, Antoinette / Herpin, Daniel / Lefebvre, Hervé. ·Unité d'hypertension, hôpital universitaire de Genève, Genève, Switzerland. Electronic address: Antoinette.Pechere@hcuge.ch. · Service de cardiologie, centre hospitalier universitaire de Poitiers, 86021 Poitiers, France. Electronic address: Daniel.Herpin@chu-poitiers.fr. · Service d'endocrinologie, diabète et maladies métaboliques, centre hospitalier universitaire, 76031 Rouen, France. Electronic address: herve.lefebvre@chu-rouen.fr. ·Ann Endocrinol (Paris) · Pubmed #27315759.

ABSTRACT: Spironolactone, which is a potent mineralocorticoid receptor antagonist, represents the first line medical treatment of primary aldosteronism (PA). As spironolactone is also an antagonist of the androgen and progesterone receptor, it may present side effects, especially in male patients. In case of intolerance to spironolactone, amiloride may be used to control hypokaliemia and we suggest that eplerenone, which is a more selective but less powerful antagonist of the mineralocorticoid receptor, be used in case of intolerance to spironolactone and insufficient control of hypertension by amiloride. Specific calcic inhibitors and thiazide diuretics may be used as second or third line therapy. Medical treatment of bilateral forms of PA seem to be as efficient as surgical treatment of lateralized PA for the control of hypertension and the prevention of cardiovascular and renal morbidities. This allows to propose medical treatment of PA to patients with lateralized forms of PA who refuse surgery or to patients with PA who do not want to be explored by adrenal venous sampling to determine whether they have a bilateral or lateralized form.

6 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. 2016

Zennaro, Maria-Christina / Jeunemaitre, Xavier. ·INSERM, U970, Paris Cardiovascular Research Center-PARCC, 56, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service de génétique, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, Paris, France. Electronic address: maria-christina.zennaro@inserm.fr. · INSERM, U970, Paris Cardiovascular Research Center-PARCC, 56, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service de génétique, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, Paris, France. ·Ann Endocrinol (Paris) · Pubmed #27315758.

ABSTRACT: While the majority of cases of primary aldosteronism (PA) are sporadic, four forms of autosomal-dominant inheritance have been described: familial hyperaldosteronism (FH) types I to IV. FH-I, also called glucocorticoid-remediable aldosteronism, is characterized by early and severe hypertension, usually before the age of 20 years. It is due to the formation of a chimeric gene between the adjacent CYP11B2 and CYP11B1 genes (coding for aldosterone synthase and 11β-hydroxylase, respectively). FH-I is often associated with family history of stroke before 40years of age. FH-II is clinically and biochemically indistinguishable from sporadic forms of PA and is only diagnosed on the basis of two or more affected family members. No causal genes have been identified so far and no genetic test is available. FH-III is characterized by severe and early-onset hypertension in children and young adults, resistant to treatment and associated with severe hypokalemia. Mild forms, resembling FH-II, have been described. FH-III is due to gain-of-function mutations in the KCNJ5 gene. Recently, a new autosomal-dominant form of familial PA, FH-IV, associated with mutations in the CACNA1H gene, was described in patients with hypertension and PA before the age of 10years. In rare cases, PA may be associated with complex neurologic disorder involving epileptic seizures and cerebral palsy (Primary Aldosteronism, Seizures, and Neurologic Abnormalities [PASNA]) due to de novo germline CACNA1D mutations.

7 Guideline SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. 2016

Amar, Laurence / Baguet, Jean Philippe / Bardet, Stéphane / Chaffanjon, Philippe / Chamontin, Bernard / Douillard, Claire / Durieux, Pierre / Girerd, Xaxier / Gosse, Philippe / Hernigou, Anne / Herpin, Daniel / Houillier, Pascal / Jeunemaitre, Xavier / Joffre, Francis / Kraimps, Jean-Louis / Lefebvre, Hervé / Ménégaux, Fabrice / Mounier-Véhier, Claire / Nussberger, Juerg / Pagny, Jean-Yves / Pechère, Antoinette / Plouin, Pierre-François / Reznik, Yves / Steichen, Olivier / Tabarin, Antoine / Zennaro, Maria-Christina / Zinzindohoue, Franck / Chabre, Olivier. ·Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité D'hypertension Artérielle, 75098 Paris Cedex 15, France. · Service de Cardiologie, centre d'excellence en hypertension, Clinique Mutualiste de Grenoble, 38028 Grenoble, France. · Centre François Baclesse, Service de Médecine Nucléaire, 3, Avenue du Général-Harris, 14076 Caen cedex 05, France. · CHU Grenoble-Alpes, Département de Chirurgie Thoracique, Vasculaire et Endocrinienne, 38700 La Tronche, France; Université Grenoble Alpes, LADAF-Laboratoire d'Anatomie Des Alpes Françaises, UFR de Médecine, 38700 La Tronche, France. · Centre Hospitalo-Universitaire Rangueil, Service de Médecine Interne et d'Hypertension Artérielle, 31059 Toulouse, France. · Service d'endocrinologie et des maladies métaboliques, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France. · Santé Publique et Informatique Médicale, Hôpital Européen Georges Pompidou, 20, Rue Leblanc, 75908 Paris cedex 15, France; Centre Cochrane Français, Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, 75098 Paris France. · Pôle Cœur Métabolisme, Unité de Prévention Cardiovasculaire, Groupe Hospitalier Universitaire Pitié-Salpêtrière, 83, bld de l'Hôpital, 75013 Paris, France. · Service de Cardiologie/Hypertension CHU Bordeaux, 33076 Bordeaux, France. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité d'Hypertension, 20, Rue Leblanc, 75908 Paris cedex 15, France. · Service de Cardiologie, Centre Hospitalier Universitaire de Poitiers, 86021 Poitiers, France. · Département des maladies rénales et métaboliques, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France. · INSERM, UMRS_970, Paris Cardiovascular Research Center, Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, 75098 Paris, France. · Centre Hospitalo-Universitaire Rangueil, Département de Radiologie, 31059 Toulouse, France. · CHU Poitiers, Hôpital Jean Bernard, Chirurgie Générale et Endocrinienne, Université de Poitiers, Faculté de Médecine, 86000 Poitiers, France. · Service d'endocrinologie, Centre Hospitalier Universitaire, 76031 Rouen, France. · Sorbonne Universités, UPMC Univ Paris 06, Faculté de Médecine, 75006 Paris, France; AP-HP, Pitié Salpétrière, Service de Chirurgie Digestive et Viscérale, 75013 Paris, France. · Service de Médecine Vasculaire et Hypertension Artérielle, Centre Hospitalier Universitaire de Lille, 59037 Lille, France. · Service de Médecine Interne (unité vasculaire et d'hypertension), Centre Hospitalier Universitaire de Lausanne, 1011 Lausanne, Switzerland. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Département de Radiologie, 20, Rue Leblanc, 75908 Paris cedex 15, France. · Unité d'Hypertension, Hopital Universitaire de Genève, 1205 Geneve, Switzerland. · Service d'Endocrinologie et Maladies Métaboliques, CHU Côte de Nacre, 14033 Caen Cedex, France. · AP-HP, hôpital Tenon, Service de Médecine Interne, 75020 Paris, France. · Service d'Endocrinologie, Hôpital Haut Lévêque, CHU de Bordeaux, Avenue de Magellan, 33600 Pessac, France. · INSERM, UMRS_970, Paris Cardiovascular Research Center, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, 75098 Paris, France. · Sorbonne Paris Cité, Université Paris Descartes, Faculté de Médecine, 75006 Paris, France. · AP-HP, HEGP, Service de Chirurgie Digestive, Générale et Cancérologique, 75015 Paris, France; Endocrinologie, Pavillon des Ecrins, Centre Hospitalier Universitaire de Grenoble, CS 10217, 38043 Grenoble Cedex 9, France. Electronic address: OlivierChabre@chu-grenoble.fr. ·Ann Endocrinol (Paris) · Pubmed #27315757.

ABSTRACT: The French Endocrinology Society (SFE) French Hypertension Society (SFHTA) and Francophone Endocrine Surgery Association (AFCE) have drawn up recommendations for the management of primary aldosteronism (PA), based on an analysis of the literature by 27 experts in 7 work-groups. PA is suspected in case of hypertension associated with one of the following characteristics: severity, resistance, associated hypokalemia, disproportionate target organ lesions, or adrenal incidentaloma with hypertension or hypokalemia. Diagnosis is founded on aldosterone/renin ratio (ARR) measured under standardized conditions. Diagnostic thresholds are expressed according to the measurement units employed. Diagnosis is established for suprathreshold ARR associated with aldosterone concentrations >550pmol/L (200pg/mL) on 2 measurements, and rejected for aldosterone concentration<240pmol/L (90pg/mL) and/or subthreshold ARR. The diagnostic threshold applied is different if certain medication cannot be interrupted. In intermediate situations, dynamic testing is performed. Genetic forms of PA are screened for in young subjects and/or in case of familial history. The patient should be informed of the results expected from medical and surgical treatment of PA before exploration for lateralization is proposed. Lateralization is explored by adrenal vein sampling (AVS), except in patients under 35 years of age with unilateral adenoma on imaging. If PA proves to be lateralized, unilateral adrenalectomy may be performed, with adaptation of medical treatment pre- and postoperatively. If PA is non-lateralized or the patient refuses surgery, spironolactone is administered as first-line treatment, replaced by amiloride, eplerenone or calcium-channel blockers if insufficiently effective or poorly tolerated.

8 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery. 2016

Steichen, Olivier / Amar, Laurence / Chaffanjon, Philippe / Kraimps, Jean-Louis / Ménégaux, Fabrice / Zinzindohoue, Franck. ·Service de médecine interne, hôpital Tenon, AP-HP, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, faculté de médecine, 75006 Paris, France. Electronic address: olivier.steichen@tnn.aphp.fr. · Unité d'hypertension artérielle, AP-HP, HEGP, 75015 Paris, France; Sorbonne Paris Cité, université Paris Descartes, faculté de médecine, 75006 Paris, France. · CHU Grenoble, département de chirurgie thoracique, vasculaire et endocrinienne, 38700 La Tronche, France; Laboratoire d'anatomie des Alpes françaises (LADAF), université Grenoble Alpes, UFR de médecine, 38700 La Tronche, France. · Chirurgie générale et endocrinienne, hôpital Jean-Bernard, CHU de Poitiers, 86000 Poitiers, France; Faculté de médecine, université de Poitiers, 86000 Poitiers, France. · Sorbonne universités, UPMC université Paris 06, faculté de médecine, 75006 Paris, France; Service de chirurgie digestive et viscérale, AP-HP, Pitié-Salpétrière, 75013 Paris, France. · Sorbonne Paris Cité, université Paris Descartes, faculté de médecine, 75006 Paris, France; Service de chirurgie digestive, générale et cancérologique, AP-HP, HEGP, 75015 Paris, France. ·Ann Endocrinol (Paris) · Pubmed #27297451.

ABSTRACT: Treatment of primary aldosteronism (PA) aims at preventing or correcting hypertension, hypokalemia and target organ damage. Patients with lateralized PA and candidates for surgery may be managed by laparoscopic adrenalectomy. Partial adrenalectomy and non-surgical ablation have no proven advantage over total adrenalectomy. Intraoperative morbidity and mortality are low in reference centers, and day-surgery is warranted in selected cases. Spironolactone administered during the weeks preceding surgery controls hypertension and hypokalemia and may prevent postoperative hypoaldosteronism. In most cases, surgery corrects hypokalemia, improves control of hypertension and reduces the burden of pharmacologic treatment; in about 40% of cases, it resolves hypertension. However, success in controlling hypertension and reversing target organ damage is comparable with mineralocorticoid receptor antagonists. Informed patient preference with regard to surgery is thus an important factor in therapeutic decision-making.

9 Guideline 8 USPSTF recommendations FPs need to know about. 2016

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email: campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #27275937.

ABSTRACT: Treat high blood pressure only if measurements taken outside of the office confirm an initial high BP reading · Screen blood-glucose levels in overweight/obese individuals 40 to 70 years old · and more.

10 Guideline SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. 2016

Douillard, Claire / Houillier, Pascal / Nussberger, Juerg / Girerd, Xavier. ·Service d'endocrinologie et des maladies métaboliques, centre hospitalier régional universitaire de Lille, 59037 Lille, France. Electronic address: claire.douillard@chru-lille.fr. · Département des maladies rénales et métaboliques, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France. Electronic address: pascal.houillier@egp.aphp.fr. · Service de médecine interne, unité vasculaire et d'hypertension, centre hospitalier universitaire de Lausanne, CH-1011 Lausanne, Switzerland. Electronic address: Juerg.Nussberger@chuv.ch. · Pôle cœur métabolisme, unité de prévention cardiovasculaire, groupe hospitalier universitaire Pitié-Salpêtrière, 83, boulevard de l'Hôpital, 75013 Paris, France. ·Ann Endocrinol (Paris) · Pubmed #27177498.

ABSTRACT: In patients with suspected primary aldosteronism (PA), the first diagnostic step, screening, must have high sensitivity and negative predictive value. The aldosterone-to-renin ratio (ARR) is used because it has higher sensitivity and lower variability than other measures (serum potassium, plasma aldosterone, urinary aldosterone). ARR is calculated from the plasma aldosterone (PA) and plasma renin activity (PRA) or direct plasma renin (DR) values. These measurements must be taken under standard conditions: in the morning, more than 2hours after awakening, in sitting position after 5 to 15minutes, with normal dietary salt intake, normal serum potassium level and without antihypertensive drugs significantly interfering with the renin-angiotensin-aldosterone system. To rule out ARR elevation due to very low renin values, ARR screening is applied only if aldosterone is>240pmol/l (90pg/ml); DR values<5mIU/l are assimilated to 5mIU/l and PRA values<0.2ng/ml/h to 0.2ng/ml/h. We propose threshold ARR values depending on the units used and a conversion factor (pg to mIU) for DR. If ARR exceeds threshold, PA should be suspected and exploration continued. If ARR is below threshold or if plasma aldosterone is<240pmol/l (90pg/ml) on two measurements, diagnosis of PA is excluded.

11 Guideline Chapter 28 Hypertensive disorders of pregnancy and eclampsia. 2016

Staff, Anne Cathrine Annetine / Andersgaard, Alice Beathe / Henriksen, Tore / Langesæter, Eldrid / Magnussen, Elisabeth / Michelsen, Trond Melbye / Thomsen, Liv Cecilie / Øian, Pål. ·Department of Obstetrics, Oslo University Hospital, Oslo, Norway; University of Oslo, The Medical Faculty, Oslo, Norway. Electronic address: Annetine.Staff@ous-hf.no. · South-Eastern Norway Regional Health Authorities, Norway. · Department of Obstetrics, Oslo University Hospital, Oslo, Norway; University of Oslo, The Medical Faculty, Oslo, Norway. · Department of Anesthesiology, Oslo University Hospital, Oslo, Norway. · Department of Obstetrics and Gynecology, St Olav's Hospital, Trondheim, Norway. · Department of Obstetrics, Oslo University Hospital, Oslo, Norway. · Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. · Department of Obstetrics and Gynecology, Tromsø University Hospital, Tromsø, Norway. ·Eur J Obstet Gynecol Reprod Biol · Pubmed #27160502.

ABSTRACT: -- No abstract --

12 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? 2016

Baguet, Jean-Philippe / Steichen, Olivier / Mounier-Véhier, Claire / Gosse, Philippe. ·Service de cardiologie, groupe hospitalier mutualiste, 38028 Grenoble, France. Electronic address: jp.baguet@ghm-grenoble.fr. · Service de médecine interne, hôpital Tenon, 75020 Paris, France. · Service de médecine vasculaire et hypertension artérielle, centre hospitalier universitaire, 59037 Lille, France. · Service de cardiologie/hypertension, CHU, 33075 Bordeaux, France. ·Ann Endocrinol (Paris) · Pubmed #27087531.

ABSTRACT: Depending on the study, the prevalence of primary aldosteronism (PA) in patients with hypertension varies from 6 to 18%. Prevalence is higher in each of the following conditions, any one of which requires screening for PA: severe hypertension (systolic blood pressure [BP]≥180mmHg and/or diastolic BP≥110mmHg); resistant hypertension (systolic BP≥140mmHg and/or diastolic BP≥90mmHg despite adherence to a tritherapy including a thiazide diuretic); hypertension associated with hypokalemia (either spontaneous or associated with a diuretic); Hypertension or hypokalemia associated with adrenal incidentaloma. It should be borne in mind that PA can induce hypertension without hypokalemia or, less frequently, hypokalemia without hypertension. Finally, as cardiovascular and renal morbidity in PA is greater than in essential hypertension of equivalent level, screening for PA is indicated when cardiovascular or renal morbidity is more severe than predicted from BP level.

13 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis. 2016

Bardet, Stéphane / Chamontin, Bernard / Douillard, Claire / Pagny, Jean-Yves / Hernigou, Anne / Joffre, Francis / Plouin, Pierre-François / Steichen, Olivier. ·Service de médecine nucléaire, centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 05, France. Electronic address: sbardet@baclesse.unicancer.fr. · Service de médecine interne et d'hypertension artérielle, centre hospitalo-universitaire Rangueil, 31059 Toulouse, France. Electronic address: chamontin.b@chu-toulouse.fr. · Service d'endocrinologie et des maladies métaboliques, hôpital Huriez, centre hospitalier régional universitaire de Lille, rue Polonovski, 59037 Lille, France. Electronic address: douillard.claire@gmail.com. · Département de radiologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75908 Paris, France. Electronic address: jean-yves.pagny@egp.aphp.fr. · Département de radiologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75908 Paris, France. Electronic address: anne.hernigou@egp.aphp.fr. · Département de radiologie, centre hospitalo-universitaire Rangueil, 31059 Toulouse, France. Electronic address: francis.joffre0626@orange.fr. · Unité d'hypertension, Assistance publique-Hôpitaux de Paris, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75908 Paris cedex 15, France. Electronic address: pierre-francois.plouin@egp.aphp.fr. · Assistance publique-Hôpitaux de Paris, hôpital Tenon, service de médecine interne, rue de la Chine, 75020 Paris, France. Electronic address: olivier.steichen@tnn.aphp.fr. ·Ann Endocrinol (Paris) · Pubmed #27036860.

ABSTRACT: To establish the cause of primary aldosteronism (PA), it is essential to distinguish unilateral from bilateral adrenal aldosterone secretion, as adrenalectomy improves aldosterone secretion and controls hypertension and hypokalemia only in the former. Except in the rare cases of type 1 or 3 familial hyperaldosteronism, which can be diagnosed genetically and are not candidates for surgery, lateralized aldosterone secretion is diagnosed on adrenal CT or MRI and adrenal venous sampling. Postural stimulation tests and (131)I-norcholesterol scintigraphy have poor diagnostic value and (11)C-metomidate PET is not yet available. We recommend that adrenal CT or MRI be performed in all cases of PA. Imaging may exceptionally identify adrenocortical carcinoma, for which the surgical objectives are carcinologic, and otherwise shows either normal or hyperplastic adrenals or unilateral adenoma. Imaging alone carries a risk of false positives in patients over 35 years of age (non-aldosterone-secreting adenoma) and false negatives in all patients (unilateral hyperplasia). We suggest that all candidates for surgery over 35 years of age undergo adrenal venous sampling, simultaneously in both adrenal veins, without ACTH stimulation, to confirm the unilateral form of the hypersecretion. Sampling results should be confirmed on adrenal vein cortisol assay showing a concentration at least double that found in peripheral veins. Aldosterone secretion should be considered lateralized when aldosterone/cortisol ratio on the dominant side is at least 4-fold higher than contralaterally.

14 Guideline [Key recommendations of the clinical guidelines of arterial hypertension in primary care]. 2016

Valenzuela-Flores, Adriana Abigail / Solórzano-Santos, Fortino / Valenzuela-Flores, Alma Gabriela / Durán-Arenas, Luis G / Ponce de León-Rosales, Samuel / Oropeza-Martínez, M Patricia / Gómez-García, Jesús Alejandro / Moreno-Ruiz, Luis A / Martínez-Vargas, Romel / Hernández-Amezcua, Lucía / Escobar-Rodríguez, David / Martínez-Flores, Enrique / Viniegra-Osorio, Arturo / Oest-Dávila, Cecilio Walterio / Soria-Guerra, Mariana. ·Coordinación Técnica de Excelencia Clínica, Unidad de Atención Médica, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Ciudad de México, México. abigail.val@gmail.com. · ·Rev Med Inst Mex Seguro Soc · Pubmed #26960054.

ABSTRACT: BACKGROUND: Hypertension ranks first medical care in first level units. It is estimated that half of the patients with hypertension are uncontrolled. The purpose of this document is to provide recommendations to guide diagnosis and treatment of arterial hypertension in primary care, which have been considered key to the process of care, in order to help health professionals in the clinical decision-making. METHODS: The guide is integrated with recommendations of international guidelines and evidence of published studies indicated the changes regarding the management and treatment of hypertension, as well as differences between the target populations of the guide. Searching for information it is performed by means of a standardized sequence in PubMed and Cochrane Library Plus, from the questions asked. The key recommendations were chosen by a consensus of a group of professionals and health managers. CONCLUSIONS: The key recommendations evidence-based standardized help you make decisions about prevention, diagnosis and treatment in patients with hypertension, and will contribute to reducing cardiovascular risk, promote changes in lifestyle, control the disease and reduce complications.

15 Guideline Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Antihypertensives. 2016

Klugman, Darren / Goswami, Elizabeth S / Berger, John T. ·1Department of Critical Care Medicine and Cardiology, Children's National Medical Center, Washington, DC. 2Department of Pharmacy, Riley Hospital for Children, Indianapolis, IN. 3Department of Pediatrics, Children's National Medical Center, Washington, DC. · ·Pediatr Crit Care Med · Pubmed #26945324.

ABSTRACT: OBJECTIVE: Hypertension remains a common condition in pediatric cardiac intensive care. The physiologic effects of hypertension in this population are complex and are impacted by patient age, comorbidities, and primary cardiac disease. The objective of this study is to review current pharmacotherapies for the management of systemic hypertension in the pediatric cardiac ICU. DATA SOURCES: Relevant literature to the treatment of systemic hypertension in children was included. Specific focus was given to literature studying the use of therapies in critically ill children and those with heart disease. Reference textbooks and drug packaging inserts were used for drug-specific pediatric guidelines. STUDY SELECTION: A search of MEDLINE, PubMed, and the Cochrane Database was performed to find literature about the management of hypertension in children. Metaanalyses and pediatric-specific studies were primarily considered and cross-referenced. Pertinent adult studies were included. DATA EXTRACTION: Once the studies for inclusion were finalized, priority for data extraction was given to pediatric-specific studies that focused on children with heart disease and critical illness. CONCLUSIONS: Systemic hypertension is common, and there is significant heterogeneity in the patient population with critical heart disease. There are limited large, prospective analyses of safety and efficacy for pediatric drug antihypertensive agents. Despite patient heterogeneity, most pharmacotherapies are safe and efficacious.

16 Guideline The measurement of adult blood pressure and management of hypertension before elective surgery: Joint Guidelines from the Association of Anaesthetists of Great Britain and Ireland and the British Hypertension Society. 2016

Hartle, A / McCormack, T / Carlisle, J / Anderson, S / Pichel, A / Beckett, N / Woodcock, T / Heagerty, A. ·Department of Anaesthesia and Intensive Care, St Mary's Hospital, London, UK. · Whitby Group Practice/British Hypertension Society, Spring Vale Medical Centre, Whitby, UK. · Departments of Anaesthesia, Peri-operative Medicine and Intensive Care, Torbay Hospital, Torquay, UK. · Institute of Cardiovascular Sciences/British Hypertension Society, University of Manchester, Manchester, UK. · Department of Anaesthesia, Manchester Royal Infirmary, Manchester, UK. · Department of Ageing and Health, Guys' and St Thomas' Hospital/British Hypertension Society, London, UK. · Hampshire, UK. · Department of Medicine, University of Manchester/British Hypertension Society, Manchester, UK. ·Anaesthesia · Pubmed #26776052.

ABSTRACT: This guideline aims to ensure that patients admitted to hospital for elective surgery are known to have blood pressures below 160 mmHg systolic and 100 mmHg diastolic in primary care. The objective for primary care is to fulfil this criterion before referral to secondary care for elective surgery. The objective for secondary care is to avoid spurious hypertensive measurements. Secondary care should not attempt to diagnose hypertension in patients who are normotensive in primary care. Patients who present to pre-operative assessment clinics without documented primary care blood pressures should proceed to elective surgery if clinic blood pressures are below 180 mmHg systolic and 110 mmHg diastolic.

17 Guideline Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. 2015

Siu, Albert L / Anonymous7120845. · ·Ann Intern Med · Pubmed #26458123.

ABSTRACT: DESCRIPTION: Update of the 2007 U.S. Preventive Services Task Force (USPSTF) reaffirmation recommendation statement on screening for high blood pressure in adults. METHODS: The USPSTF reviewed the evidence on the diagnostic accuracy of different methods for confirming a diagnosis of hypertension after initial screening and the optimal rescreening interval for diagnosing hypertension. POPULATION: This recommendation applies to adults aged 18 years or older without known hypertension. RECOMMENDATION: The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. (A recommendation) The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.

18 Guideline Evidence-Based Guideline of the German Nutrition Society: Fat Intake and Prevention of Selected Nutrition-Related Diseases. 2015

Wolfram, Günther / Bechthold, Angela / Boeing, Heiner / Ellinger, Sabine / Hauner, Hans / Kroke, Anja / Leschik-Bonnet, Eva / Linseisen, Jakob / Lorkowski, Stefan / Schulze, Matthias / Stehle, Peter / Dinter, Jessica / Anonymous3300844. · ·Ann Nutr Metab · Pubmed #26414007.

ABSTRACT: As nutrition-related chronic diseases have become more and more frequent, the importance of dietary prevention has also increased. Dietary fat plays a major role in human nutrition, and modification of fat and/or fatty acid intake could have a preventive potential. The aim of the guideline of the German Nutrition Society (DGE) was to systematically evaluate the evidence for the prevention of the widespread diseases obesity, type 2 diabetes mellitus, dyslipoproteinaemia, hypertension, metabolic syndrome, coronary heart disease (CHD), stroke, and cancer through the intake of fat or fatty acids. The main results can be summarized as follows: it was concluded with convincing evidence that a reduced intake of total and saturated fat as well as a larger intake of polyunsaturated fatty acids (PUFA) at the expense of saturated fatty acids (SFA) reduces the concentration of total and low-density lipoprotein cholesterol in plasma. Furthermore, there is convincing evidence that a high intake of trans fatty acids increases risk of dyslipoproteinaemia and that a high intake of long-chain polyunsaturated n-3 fatty acids reduces the triglyceride concentration in plasma. A high fat intake increases the risk of obesity with probable evidence when total energy intake is not controlled for (ad libitum diet). When energy intake is controlled for, there is probable evidence for no association between fat intake and risk of obesity. A larger intake of PUFA at the expense of SFA reduces risk of CHD with probable evidence. Furthermore, there is probable evidence that a high intake of long-chain polyunsaturated n-3 fatty acids reduces risk of hypertension and CHD. With probable evidence, a high trans fatty acid intake increases risk of CHD. The practical consequences for current dietary recommendations are described at the end of this article.

19 Guideline 2015 guidelines for the management of hypertension. Recommendations of the Polish Society of Hypertension - short version. 2015

Tykarski, Andrzej / Narkiewicz, Krzysztof / Gaciong, Zbigniew / Januszewicz, Andrzej / Litwin, Mieczysław / Kostka-Jeziorny, Katarzyna / Adamczak, Marcin / Szczepaniak-Chicheł, Ludwina / Chrostowska, Marzena / Czarnecka, Danuta / Dzida, Grzegorz / Filipiak, Krzysztof J / Gąsowski, Jerzy / Głuszek, Jerzy / Grajek, Stefan / Grodzicki, Tomasz / Kawecka-Jaszcz, Kalina / Wożakowska-Kapłon, Beata / Begier-Krasińska, Beata / Manitius, Jacek / Myśliwiec, Małgorzata / Niemirska, Anna / Prejbisz, Aleksander / Pupek-Musialik, Danuta / Brzezińska-Rajszys, Grażyna / Stolarz-Skrzypek, Katarzyna / Szadkowska, Agnieszka / Tomasik, Tomasz / Widecka, Krystyna / Więcek, Andrzej / Windak, Adam / Wolf, Jacek / Zdrojewski, Tomasz / Żurowska, Aleksandra. ·tykarski@o2.pl. · ·Kardiol Pol · Pubmed #26304155.

ABSTRACT: -- No abstract --

20 Guideline [Update on Current Care Guideline: Diabetic retinopathy]. 2015

Summanen, Paula / Kallioniemi, Vuokko / Komulainen, Jorma / Eriksson, Lars / Forsvik, Heikki / Hietala, Kustaa / Tulokas, Sirkku / Von Wendt, Gunvor / Anonymous6060838. · ·Duodecim · Pubmed #26237887.

ABSTRACT: Good treatment of diabetes decreases the risk of diabetic retinopathy. The goals of the treatment are adequate glucose balance, blood pressure and prevention of metabolic syndrome. Every patient with diabetes should regularly be screened for diabetic retinopathy. Timely and efficient treatment of retinopathy significantly decreases the risk of visual impairment.


Anonymous6140835 / Zabolotskikh, I B / Lebedinskii, K M / Grigor'ev, E V / Grigor'ev, S V / Gritsan, A I / Likhvantsev, V V / Mizikov, V M / Potievskaia, V I / Rudnov, V A / Subbotin, V V. · ·Anesteziol Reanimatol · Pubmed #26148370.

ABSTRACT: These clinical guidelines apply to the implementation of health care for all patients with concomitant hypertension in the perioperative period in a hospital. The guidelines specify the method of stratifying the risk of perioperative cardiac complications. We described methods for the treatment of urgent conditions with hypertension and hypertensive crises and identified the main features of the preoperative evaluation and preparation of patients with concomitant hypertension. The clinical guidelines contain recommendations on the management of intra- and postoperative period

22 Guideline [Turkish Hypertension Consensus Report]. 2015

Arıcı, Mustafa / Birdane, Alparslan / Güler, Kerim / Yıldız, Bülent Okan / Altun, Bülent / Ertürk, Şehsuvar / Aydoğdu, Sinan / Özbakkaloğlu, Mert / Ersöz, Halil Önder / Süleymanlar, Gültekin / Tükek, Tufan / Tokgözoğlu, Lale / Erdem, Yunus / Anonymous5410835 / Anonymous5420835 / Anonymous5430835 / Anonymous5440835 / Anonymous5450835. ·Department of Internal Medicine, Division of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey. marici@hacettepe.edu.tr. · Department of Cardiology, Osmangazi University Faculty of Medicine, Eskişehir, Turkey. · Department of Internal Medicine, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey. · Department of Internal Medicine, Division of Endocrinology and Metabolic Diseases, Hacettepe University Faculty of Medicine, Ankara, Turkey. · Department of Internal Medicine, Division of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey. · Department of Internal Medicine, Division of Nephrology, Ankara University Faculty of Medicine, Ankara. · Department of Cardiology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey. · Turkey Internal Medicine Specialists Association, Ankara, Turkey. · Department of Internal Medicine, Division of Endocrinology and Metabolic Diseases, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey. · Department of Internal Medicine, Division of Nephrology, Akdeniz University Faculty of Medicine, Antalya, Turkey. · Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey. · ·Turk Kardiyol Dern Ars · Pubmed #26142798.

ABSTRACT: Hypertension is a common and important public health problem in Turkey and worldwide. Recommendations on the diagnosis and treatment of hypertension have been presented in many nationally and internationally agreed European and American guidelines. However, there are differences among these guidelines, and some of the recommendations are not consistent with clinical practice in our country. Consensus report preparation, with the participation of relevant associations, was considered necessary to merge recommendations by evaluating hypertension guidelines from the perspective of Turkey and to create a joint approach in the diagnosis and treatment of hypertension in adults. For this purpose, it was aimed to prepare a practical text in Turkey in which all physicians dealing with hypertensive patients, from family practitioners in primary care to specialists in tertiary care, could come to agreement on common concepts, and which would be used as a basic reference guideline. Considering health care practices and sociocultural structure in Turkey, this report aimed to enhance awareness on hypertension, provide a common basis for different definitions and values as well as therapeutic options in various guidelines, and establish a practical reference guide to improve clinical practices in Turkey. This report is not a document describing hypertension in every aspect, but a reference, including basic recommendations with outlines. Care was taken to ensure that recommendations were evidence-based and valid for a majority of patients in clinical practice. However, it should be kept in mind that an approach assessment should be made on an individual basis for each patient.

23 Guideline 2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure. 2015

Handler, Joel. ·Expert Panel Member of the Eighth Joint National Committee on High Blood Pressure; Hypertension Clinical Lead, Care Management Institute; and Hypertension Lead for Southern California Kaiser Permanente, Anaheim, CA. joel.handler@kp.org. ·Perm J · Pubmed #26057683.

ABSTRACT: The 2014 Kaiser Permanente Care Management Institute National Hypertension Guideline was developed to assist primary care physicians and other health care professionals in the outpatient treatment of uncomplicated hypertension in adult men and nonpregnant women aged 18 years and older. A major practice change is the recommendation for goal systolic blood pressure less than 150 mmHg in patients aged 60 years and older who are treated for hypertension in the absence of diabetes or chronic kidney disease. This article describes the reasons for, evidence for, and consequences of the change, and includes the guideline.

24 Guideline Standards for ambulatory blood pressure monitoring clinical reporting in daily practice: recommendations from the Italian Society of Hypertension. 2015

Omboni, Stefano / Palatini, Paolo / Parati, Gianfranco / Anonymous7410832. ·aClinical Research Unit, Italian Institute of Telemedicine, Varese bDepartment of Medicine, University of Padua, Padua cDepartment of Health Sciences, University of Milano-Bicocca dDepartment of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, Milan, Italy. · ·Blood Press Monit · Pubmed #26049213.

ABSTRACT: This paper aims to provide practical indications to healthcare professionals and manufacturers of ambulatory blood pressure monitoring (ABPM) devices on the characteristics and minimum required contents of a standard ABPM report to be used in the clinical practice. Such indications will help make ABPM reports more easily interpretable and independent from the ABPM device and software used. The first important and unavoidable step of ABPM reporting is a quality assessment: if a recording does not meet the minimum requirements for quality criteria, the reporting physician should advise the patient to repeat the test and should not further proceed to a diagnostic evaluation and interpretation of the recording. A basic clinical report must contain the list of each single reading, the graphical display of individual readings and hourly average values, the mean, minimum and maximum values, and SDs of blood pressure and heart rate values for the 24 h, daytime and night-time, day-night differences, and blood pressure loads. The final medical report should be prepared in a quite logically structured way, considering the following: (i) a judgment on the overall quality of the 24 h recording; (ii) an indication of whether average 24 h, daytime and night-time systolic, and diastolic blood pressure values are within or above the normal limits; and (iii) a description of the 24 h pattern of blood pressure fluctuations. A final general statement on the normotensive or hypertensive status and on the degree of blood pressure control in case of treated patients should also be provided.

25 Guideline Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015

Rosendorff, Clive / Lackland, Daniel T / Allison, Matthew / Aronow, Wilbert S / Black, Henry R / Blumenthal, Roger S / Cannon, Christopher P / de Lemos, James A / Elliott, William J / Findeiss, Laura / Gersh, Bernard J / Gore, Joel M / Levy, Daniel / Long, Janet B / O'Connor, Christopher M / O'Gara, Patrick T / Ogedegbe, Gbenga / Oparil, Suzanne / White, William B / Anonymous7990825. · ·Circulation · Pubmed #25829340.

ABSTRACT: -- No abstract --